Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations

Inclusion Criteria: Subjects must meet all the following criteria for study entry:

1. Patient who agreed to participate in the KOSMOS-II master observation study
2. 19 years of age or older
3. Patients with BRAF V600 mutated advanced solid tumor (excluding BRAF V600E/K mutatedmalignant melanoma, BRAF V600E mutated non-small cell lung cancer, and BRAF V600Emutated colorectal cancer)
4. Patients with other BRAF gene alterations that are regarded to be actionable by theKOSMOS MTB
5. Disease progression after ≥ 1-prior line of systemic treatment and no standardtreatment option
6. ECOG performance status score 0-2
7. Life expectancy of > 3 months
8. Measurable or evaluable disease according to RECIST version 1.1
9. Ability to take oral medications
10. Adequate bone marrow and organ function
11. Patients who voluntarily decided to participate after understanding this clinicaltrial, and signed a written informed consent

Exclusion Criteria: Subjects who meet any of the following criteria will be excluded from study entry:

1. Prior treatment with a BRAF inhibitor (including, but not limited to, dabrafenib,vemurafenib, encorafenib) or MEK inhibitor (including, but not limited to, trametinib,binimetinib, selumetinib, cobimetinib) or ERK inhibitor (including, but not limitedto, ravoxertinib, ulixertinib, CC-90003, MK-8353)
2. History of malignancies with confirmed activating RAS mutation.
3. Hypersensitivity to the active ingredients and additives of investigational product.
4. Presence of any unresolved ≥Grade 2 (per Common Terminology Criteria for AdverseEvents (CTCAE) version 5.0) toxicity from previous anti-cancer therapy at the time ofenrollment. (Except toxicities which are not clinically significant such as alopecia,skin discoloration, and neuropathy).
5. Any anti-cancer treatment (local treatment, chemotherapy, immunotherapy, targetedtherapy) within 2 weeks prior to the start of study treatment.
6. Prior major surgery less than 14 days before enrollment. Any surgery-related AE musthave been resolved before enrollment.
7. Prior radiotherapy less than 14 days before enrollment, except for ATC (radiotherapyis not permitted within 7 days before enrollment).
8. Known additional malignancy that is progressing or has required active treatmentwithin the past 3 years. (Patient with a history of completely resected non-melanomaskin cancer or successfully treated in situ carcinoma is potentially eligible).
9. Presence of central nervous system metastases that are symptomatic or untreated or notstable for ≥3 months or requiring corticosteroids.
10. Symptomatic or untreated leptomeningeal or spinal cord compression. Subjects who havebeen previously treated for these conditions are asymptomatic and currently not takingcorticosteroids before enrollment, is permitted.
11. Current evidence of cardiovascular risk including any of the following:

• Left ventricular ejection fraction (LVEF) below the institutional lower limit ofnormal
• QT interval corrected for heart rate using Bazett's formula ≥ 480 msec
• Clinically significant uncontrolled arrhythmias
• Moderate valvular thickening documented by echocardiography
• Presence of intra-cardiac defibrillators
• Acute coronary syndromes (including myocardial infarction and unstable angina)which required coronary angioplasty or stenting within 6 months before enrollment
• Congestive heart failure ≥ Class II as defined by New York Heart Association

12. Current evidence or history of retinal vein occlusion
13. Pregnant or lactating women
14. Patients who do not consent to adequate contraception throughout the study period

• Women of childbearing potential should use effective contraception* until 16weeks after the last investigational product administration
• Male patients who have not undergone a vasectomy must consent to the use ofappropriate contraception* and are prohibited from providing sperm for up to 16weeks after administration of the last investigational product * Appropriatecontraception: hormonal contraceptives (subcutaneous formulas, injections, oralcontraceptives, etc.), intrauterine devices (IUD, Intra Uterine Device or IUS,Intra Uterine System), sterilization by participants or participant's partner (vasectomy, tubal ligation, etc.); Double blocking (a method that uses acombination of blocking methods, such as using a cervical cap or a contraceptivediaphragm with a male condom)

15. Active infection such as hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)

• For HBsAg is positive, and HBV DNA ≤ LLOQ, enrollment of the subject can beconsidered.
• If the patient with chronic hepatitis B who are HBsAg positive and HBV DNApositive has been taking antiviral drugs for more than 3 months, enrollment ofthe subject can be considered at the investigator's discretion.
• For IgG anti-HBc is positive (a history of HBV infection) and HBV DNA ≤ LLOQ,enrollment of the subject can be considered.
• For Anti-HCV Ab is positive, and HCV RNA ≤ LLOQ, enrollment of the subject can beconsidered.

16. Acute/chronic medical or psychiatric abnormalities
17. The investigator judges that it is not appropriate to participate in this study forelse reasons.